Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: soluble guanylate cyclase stimulants - Bayer

Drug Profile

Research programme: soluble guanylate cyclase stimulants - Bayer

Alternative Names: BAY 41-2272; BAY 54-6544

Latest Information Update: 28 Jul 2022

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Bayer
  • Class Antihyperlipidaemics; Antihypertensives; Antiplatelets; Pyrazoles; Pyridines; Small molecules
  • Mechanism of Action Guanylate cyclase stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Atherosclerosis
  • Discontinued Heart failure; Hypertension

Most Recent Events

  • 28 Jul 2022 No recent reports of development identified for preclinical development in Atherosclerosis in Germany (PO)
  • 21 Jun 2019 Pharmacodynamics data from a preclinical studies in the Hypertension presented at the 29th European Meeting on Hypertension and Cardiovascular Protection (ESH-2019)
  • 27 Aug 2018 Preclinical data for Atherosclerosis presented at the Annual Congress of the European Society of Cardiology (ESC Congress-2018)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top